#South Korea #Seoul #ImmunoForge #PF1801 #PF1804

ImmunoForge at the 2026 J.P. Morgan Healthcare Conference

ImmunoForge Co., Ltd., a biopharmaceutical company based in South Korea that specializes in treatments for rare diseases, has announced its participation in the upcoming J.P. Morgan Healthcare Conference 2026, taking place from January 12 to 15 in San Francisco. The company’s Co-CEOs, Sung-Min Ahn and Kiho Chang, will lead strategic 1-on-1 meetings with major pharmaceutical firms and investors during this prestigious event. The focus of these discussions will be on global out-licensing opportunities for their Phase 2 assets PF1801 and PF1804.

Focus on High-Level Partnering Sessions

Instead of a formal presentation, ImmunoForge has chosen to engage in high-level private sessions aimed at forging strategic partnerships. The company's primary agenda is to secure alliances with potential collaborators capable of facilitating entries into the U.S. market for clinical trials focusing on their promising treatments. This approach underscores ImmunoForge's commitment to finding the right partners to advance its pipeline of innovative therapies effectively.

Highlights of ImmunoForge's Therapeutic Pipeline

1. Near-Term Assets for U.S. Clinical Trials:
- PF1801: This treatment is currently undergoing Phase 2 trials in South Korea for Polymyositis and Dermatomyositis, with U.S. FDA clearance obtained for both indications, making it prime for immediate entry into U.S. clinical trials.
- PF1804: This asset aimed at DMD-associated cardiomyopathy has also secured FDA clearance for Phase 2 trials and is poised for clinical execution with strategic partners.
- PF1807: This represents a monthly therapy for sarcopenia, presenting a unique opportunity for prevention and treatment of myositis and sarcopenia.
- KF1601: While the domestic rights have already been secured and licensed for Phase 1 launch next year in Korea, international licensing rights are up for discussion, presenting a viable option for global partners.

ImmunoForge aims to utilize its long-acting ELP (Elastin-Like Polypeptide) technology, which allows for the extension of drug half-lives, enabling less frequent dosage schedules. This technology is crucial in their efforts to stay ahead in the biopharmaceutical landscape for rare disease treatments.

Strategic Goals for the Conference

A representative from ImmunoForge noted, "Our goal for JPM 2026 week is to connect with potential partners who can facilitate rapid transitions for our FDA-cleared INDs into the U.S. market. As a lean biotech entity, we have focused on mitigating risks associated with our assets through regulatory clearances. We are eager to align with global collaborators who can navigate these programs through the next stages of clinical development and eventually into the commercial market."

In addition to establishing licensing agreements with prominent pharmaceutical companies, ImmunoForge is open to exploring NewCo models driven by investors. Through this strategy, they intend to amplify their developmental capabilities and introduce their diverse pipeline to international companies, strengthening their presence in the global market.

Scheduling Meetings at JP Morgan 2026

ImmunoForge is in the process of accepting meeting requests for the duration of the JPM Conference. Interested parties are encouraged to contact their Business Development Team via email at [email protected] to schedule a session with their executive team in San Francisco.

About ImmunoForge

ImmunoForge is a venture-backed, clinical-stage biopharmaceutical company dedicated to innovating therapies targeting muscular and rare diseases. By leveraging its proprietary long-acting ELP technology, ImmunoForge aims to improve the treatment landscape for patients suffering from these challenging health conditions. The company's lead candidate, PF1801, is currently undergoing advanced trials and has been designated as an Orphan Drug by the FDA, underscoring its potential impact within the medical community. As ImmunoForge prepares for the J.P. Morgan Healthcare Conference, it exemplifies how dynamic partnerships can propel biopharmaceutical advancements on a global scale.